linjc16/ctgov huggingface dataset:
Propensity Score Matched Comparison of HMP vs. SCS in Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
Hypothermic machine perfusion (HMP) is considered superior to static cold storage (SCS) in kidney transplantation, but the true benefit in the real-world experience remains incompletely understood. The aim of our study is to investigate the real-world impact of HMP on kidney graft function after deceased donor kidney transplant in an HMP cohort propensity score matched with SCS. Propensity score matching will be based on CIT, ECD, gender mismatch, CMV mismatch, re-TX and ET-senior program with a caliper of 0.05

Official Title
-----------------
A Retrospective Propensity Score Matched Analysis Reveals Superiority of Hypothermic Machine Perfusion Over Static Cold Storage in Deceased Donor Kidney Transplantation.

Conditions
-----------------
Delayed Graft Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: single kidney transplantation from a deceased donor at Medical University of Innsbruck between 08/2015 and 12/2019 Exclusion Criteria: combined kidney transplantation with an other organ living donor kidney transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypothermic machine perfusion (HMP)<br>patients who underwent kidney transplantation following HMP | |
| Static cold storage (SCS)<br>patients who underwent kidney transplantation following SCS | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delayed graft function (DGF) | DGF was defined as the need for at least one dialysis within the first seven days after transplant with the exception of dialysis for hyperkalemia or hypervolemia within the first 12 hours post-transplant | 7 days post transplant | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| graft survival | 24 month graft survival | 24 months post transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
kidney transplantation
Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery

Study Overview
=================
Brief Summary
-----------------
It is unknown whether post operative chewing gum will reduce post operative ileus. This study is a randomised controlled trial that will determine whether chewing gum three times a day following surgery will reduce post operative ileus. Time to passage of flatus will be used to determine that incidence of ileus.

Detailed Description
-----------------
Patients will be randomised to one of two arms, the experimental arm will be chewing gum and the control arm will be normal post operative care. The primary endpoint is time to passage of flatus (defined as end of operation to first passage of flatus, in minutes). The trial will be unblinded to patients and observers and has been powered to demonstrate a 15% reduction in passage to flatus (130 patients required)

Official Title
-----------------
Randomised Controlled Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery

Conditions
-----------------
Colorectal Cancer, Surgery

Intervention / Treatment
-----------------
* Dietary Supplement: Chewing gum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing elective colorectal surgery (open and laparoscopic), able to given informed consent Exclusion Criteria: Emergency colorectal surgery, unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chewing gum<br>Patients will chew sugar free gum three times a day | Dietary Supplement: Chewing gum<br>* Sugar free chewing gum<br>|
| No Intervention: Control<br>Normal post operative care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bowel function (as assessed by questionnaire) | Time to passage of flatus | Minutes (end of surgery to first passage of flatus, measured up to 4 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diet (as assessed by questionnaire) | Time to tolerating full diet | Minutes (end of surgery to first solid food, assessed by patient questionnaire up to 4 weeks from randomisation) | 
| Length of stay |  | Days (till successful discharge from secondary care to home or respite care measured up to first 31 days) | 
| Post op nausea and vomiting score (as recorded by visual analogue scale) | Post op nausea and vomiting score (PONV) | Recorded daily for first 5 days | 
| Morbidity | Post operative morbidity | Days (recorded up to 30 days and defined by Clavien-Dindo scale) |
Aerobic Interval Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Hypoxemia

Study Overview
=================
Brief Summary
-----------------
Patients with severe Chronic Obstructive Pulmonary Disease (COPD) and low oxygen levels in the blood are at risk of developing pulmonary hypertension and strain on the right side of the heart, both of which are known to increase symptoms and worsen prognosis It is not fully established whether interval exercise training in patients with severe COPD and concomitant low oxygen levels is beneficial. This study aims to evaluate the effects of aerobic interval exercise training in patients with severe COPD and low oxygen levels in the blood, with a particular emphasis on such effects on the cardiovascular system and pulmonary circulation.

Official Title
-----------------
Effects of Aerobic Interval Training on Cardiac Function, With Special Focus on Pulmonary Pressures and Right Sided Function, in Patients With Chronic Obstructive Pulmonary Disease and Hypoxemia

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive, Hypertension, Pulmonary, Hypoxia

Intervention / Treatment
-----------------
* Other: Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic Obstructive Pulmonary Disease (COPD) Forced Expiratory Volume 1 second (FEV1) <60% of predicted FEV1%FVC <70 % of predicted (FVC = Forced Vital Capacity) Qualify for Long term oxygen therapy (LTOT), or presence of significant desaturation on exercise. Exclusion Criteria: Unstable ischaemic heart disease or valvular heart disease. Active malignant disease. Substance abuse. Physical or mental disability that prevents participation in the exercise programme or testing. Pregnancy. Exacerbation of COPD or respiratory tract infection last 6 weeks before. Completed pulmonary rehabilitation programme or other organised exercise programme last 3 month Use of high doses of systemic steroids.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: exercise training<br>Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions. | Other: Exercise<br>* Exercise training intervention as described earlier.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary artery pressure | Examined by right heart catheterisation | Change from baseline at 10 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise Therapy
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide information about viral genotypes that may be associated with higher pathogenicity, and help to identify individuals who may be at higher risk of developing Progressive Multifocal Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus (JCV).

Detailed Description
-----------------
Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will directly seek mutations that could identify subjects at risk.

Official Title
-----------------
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Conditions
-----------------
Progressive Multifocal Leukoencephalopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Subjects who have confirmed PML while on treatment with Natalizumab NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to examine host genetic variation and possible genetic susceptibility to PML |  | Up to 3 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To explore predisposing factors of the innate and adaptive immune system |  | Up to 3 Months | 
| To analyze DNA sequences of JCV |  | Up to 3 Months | 
| optional substudy: to test alterations in DNA repair pathways |  | Up to 3 Months |
Evaluation of Long-term Coronary Stenting Outcomes in Diabetic Patients With or Without Optimal Glycemic Control

Study Overview
=================
Brief Summary
-----------------
the purpose of this study is to determine whether appropriate control of diabetes around the PCI time is related with MACE and outcome of diabetic patients.

Detailed Description
-----------------
Despite recent advances in coronary revascularization, cardiovascular disease accounts for about 75% of all hospital admissions in diabetic patients.although the introduction of drug-eluting stents has reduced the rates of restenosis after PCI, diabetic patients undergoing PCI will have poorer clinical outcomes.In this study, we sought to investigate whether a pre and post procedural glycemic control in diabetic patients,as reflected by HgbA1C prior,1 and 6 months after elective PCI,was related to major advance cardiac events (MACE) during 3 year follow up.

Official Title
-----------------
Evaluation of Long-term Coronary Stenting Outcomes in Diabetic Patients With or Without Optimal Glycemic Control Referring to Tehran Heart Center Since June 2007 to June 2009

Conditions
-----------------
Diabetes, Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18-75 coronary stenosis > 70% Exclusion Criteria: Myocardial infarction in 72 hours prior to PCI LVEF < 30% Residual Stenosis>30% Cr level > 2.0 hemodynamic compromise during intervention Left main lesions PCI for vein grafts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| controlled diabetes<br>diabetic patients with HbA1C level below 7.0% | |
| uncontrolled diabetes<br>diabetic patients with hbA1C level above 7% | |
| non-diabetic<br>patients who does not have diabetes at the time of PCI | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac event |  | during 3 years after per-cutaneous coronary intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| target vessel revascularization |  | during 3 years after PCI | 
| target lesion revascularization |  | during 3 years after PCI |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

Study Overview
=================
Brief Summary
-----------------
A single-center, open-label, parallel-group, phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LINO-1713 in healthy Korean female subjects

Official Title
-----------------
A Single-center, Open-label, Parallel-group, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: LINO-1713 1 tablet
* Drug: LINO-1713 once a day for 24 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with a Body Mass Index (BMI) between 18kg/m2   28kg/m2 Exclusion Criteria: Clinically significant cardiovascular disease, respiratory disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pharmacokinetic evaluation<br>LINO-1713 (Estetrol 15mg/Drospirenone 3mg) | Drug: LINO-1713 1 tablet<br>* LINO-1713 1 tablet is administered once. Oral administration with 200mL of water<br>|
| Experimental: Pharmacodynamic evaluation<br>LINO-1713 (Estetrol 15mg/Drospirenone 3mg) | Drug: LINO-1713 once a day for 24 days<br>* Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics parameters: Cmax |  | Before and after administration 15, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144, and 168 hours | 
| Pharmacokinetics parameters: Tmax |  | Before and after administration 15, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144, and 168 hours |
Language Function in Patients With Brain Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use an imaging method called functional magnetic resonance imaging (fMRI) in patients who have a tumor near an area of the brain that is believed to control language. The fMRI is a new kind of imaging that uses a strong magnetic field to look at functioning brain tissue. This kind of imaging will be used to study the effect of the brain tumor on your speech.

Official Title
-----------------
Reorganization of Language Function in Patients With Brain Tumors

Conditions
-----------------
Brain Cancer, CNS Cancer

Intervention / Treatment
-----------------
* Other: fMRI Scan, pre- and post language evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient in whom a tumor invades or is directly adjacent to the expected location of one of the language centers. At least 18 years of age English as first language Exclusion Criteria: Patients with high grade tumors History of significant psychiatric condition (e.g. schizophrenia, obsessive-compulsive disorder, significant dementia), History of the following neurological conditions: CVA, demyelinating conditions, cerebral palsy, Alzheimer's disease. History of significant claustrophobic reactions. Pregnancy Standard contraindications to MR examinations (e.g. implanted stimulator) Patients, who were treated prior to our first scan, will not be eligible to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>neurosurgical patients | Other: fMRI Scan, pre- and post language evaluation<br>* All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To identify language organization prior to surgery in patients in whom a tumor invades or is directly adjacent to the expected location of one of the language centers. |  | conclusion of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess language reorganization over time. |  | conclusion of study |
Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration

Study Overview
=================
Brief Summary
-----------------
Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.

Detailed Description
-----------------
Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.

Official Title
-----------------
Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men

Conditions
-----------------
Insulin Sensitivity

Intervention / Treatment
-----------------
* Drug: erythropoietin
* Drug: placebo (saline)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy persons Between 18 and 30 years Normal weight (BMI: 18-25) Exclusion Criteria: Severe heart disease (NYHA 3) Uncontrolled hypertension Previous cerebrovascular disease Proliferative retinopathy Diabetes Musculo-skeletal diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo<br>placebo | Drug: placebo (saline)<br>* i.v<br>|
| Experimental: Erythropoietin<br>acute administration of erythropoietin | Drug: erythropoietin<br>* bolus of 400 IU/kg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity |  | 4 and 6 hours post | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Substrate metabolism |  | 4 and 6 hours post | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erythropoietin, human muscle tissue, insulin sensitivity, substrate metabolism